Lonza, Cryoport Partner in Cell and Gene Therapy Field

November 21, 2019

Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics.

Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics, it was revealed in a Nov. 5, 2019 press release.

As part of the commitment, Lonza has announced that Cryoport is a preferred partner for the transport and delivery of patient tissues globally. Building on the recent partnership between Lonza and Vineti, this new collaboration will aim to provide fully integrated solutions, including co-location of manufacturing bioservices and distribution facilities, automated data management, and process optimization.

“The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients,” said Alberto Santagostino, SVP head of Cell & Gene Technologies, Lonza Pharma & Biotech, in the press release. “There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency.”

“Clinical trial activity in the cell and gene therapy sector is rapidly growing as biopharmaceutical companies discover new ways to harness regenerative therapies and combat illnesses. As more and more of these therapies approach commercialization, there is strengthening demand for reliable, integrated outsourced manufacturing and distribution solutions,” added Jerrell Shelton, CEO, Cryoport. “Our partnership agreement with Lonza, an internationally-renowned supplier to the pharma and biotech markets, will improve effectiveness, efficiency, and safety throughout the cell and gene therapy manufacturing process by integrating our temperature-controlled supply chain solutions with Lonza’s manufacturing services.”

Source: Lonza